Klassen Preston 4
4 · Regulus Therapeutics Inc. · Filed Jan 31, 2025
Insider Transaction Report
Form 4
Klassen Preston
DirectorPresident & Head of R & D
Transactions
- Award
Stock Option (Right to Buy)
2025-01-30+675,000→ 675,000 totalExercise: $1.00Exp: 2035-01-29→ Common Stock (675,000 underlying)
Footnotes (1)
- [F1]The stock option commenced vesting on January 1, 2025 and will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.